))
Welcome to the new Rare Kidney Disease Show part of the RKD Scientific Network sponsored by Travere Therapeutics. The Rare Kidney Disease Show is your primary source for cutting-edge insights, expert perspectives, and pivotal updates in nephrology. Led by our panel of experts, explore the advances in glomerular nephropathies through compelling conversations, challenging case studies, and discussions tackling hot topics. Join us as we strive to provide you with the ultimate resource to suppor ...
…
continue reading
1
The Role of Endothelin in IgAN, ft. Dr. Donald Kohan : 3
17:25
17:25
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
17:25
Episode Overview: Donald Kohan, PhD is an Emeritus Professor at the University of Utah Health with expertise in endothelin receptors, sodium transporters, and the renin-angiotensin-aldosterone system in chronic kidney disease. In this episode, Professor Kohan provides an overview of the endothelin system and how it relates to the pathophysiology of…
…
continue reading
1
Unmet Needs in IgAN: Burden of Disease & Long-Term Impact on Patients ft. Dr. Jonathan Barratt : 2
15:44
15:44
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
15:44
Overview: In this episode of the Rare Kidney Disease Show, Professor Jonathan Barratt discusses the need to take a long-term approach when managing IgA nephropathy patients. He presents data from the UK National Registry of Rare Kidney Diseases (RaDaR). During this recording you will hear Professor Barratt discussing the continued risk of progressi…
…
continue reading
1
Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1
16:15
16:15
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
16:15
Overview: In this episode of the Rare Kidney Disease Show, Dr. Rovin, Professor of Internal Medicine and Pathology at Ohio State University and chair of the RKD Scientific Network and Podcast, discusses advances in the management of IgAN through a patient case study. “IgAN progresses more often than we thought and progresses even in patients with l…
…
continue reading
